Mersana Therapeutics, Inc. - stock earnings
MRSN Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 9, 2024 BeforeMarket | - / -0.1846000000 | - | - / 8.7 million | - |
MRSN Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -19.5 million USD | 10.7 million USD |
| 2023Q3 | -41.7 million USD | 7.7 million USD |
| 2023Q2 | -54.3 million USD | 10.7 million USD |
| 2023Q1 | -57.1 million USD | 7.8 million USD |
| 2022Q4 | -45.9 million USD | 14.7 million USD |
| 2022Q3 | -60.7 million USD | 5.6 million USD |
| 2022Q2 | -53.0 million USD | 4.3 million USD |
| 2022Q1 | -48.0 million USD | 2.0 million USD |
| 2021Q4 | -49.0 million USD | 11000 USD |
| 2021Q3 | -45.5 million USD | 11000 USD |
| 2021Q2 | -40.9 million USD | 11000 USD |
| 2021Q1 | -34.7 million USD | 11000 USD |
| 2020Q4 | -28.8 million USD | 11000 USD |
| 2020Q3 | -22.5 million USD | 11000 USD |
| 2020Q2 | -19.8 million USD | 796000 USD |
| 2020Q1 | -16.9 million USD | 11000 USD |
| 2019Q4 | -16.2 million USD | 42000 USD |
| 2019Q3 | -16.8 million USD | 844000 USD |
| 2019Q2 | -17.1 million USD | 202000 USD |
| 2019Q1 | 21.9 million USD | 41.0 million USD |
| 2018Q4 | -22.4 million USD | 1.2 million USD |
| 2018Q3 | -17.1 million USD | 2.2 million USD |
| 2018Q2 | -12.4 million USD | 4.2 million USD |
| 2018Q1 | -12.4 million USD | 3.1 million USD |
| 2017Q4 | -14.0 million USD | 3.3 million USD |
| 2017Q3 | -7.7 million USD | 6.3 million USD |
| 2017Q2 | -8.9 million USD | 3.7 million USD |
| 2017Q1 | -8.1 million USD | 4.3 million USD |
| 2016Q4 | 1.3 million USD | 12.0 million USD |
| 2016Q3 | -5.8 million USD | 3.3 million USD |
| 2016Q2 | -3.8 million USD | 6.2 million USD |
| 2016Q1 | -5.4 million USD | 3.7 million USD |
| 2015Q4 | -16.4 million USD | 10.4 million USD |
MRSN Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -171.7 million USD | 36.9 million USD |
| 2022 | -207.5 million USD | 26.6 million USD |
| 2021 | -169.2 million USD | 43000 USD |
| 2020 | -88.4 million USD | 828000 USD |
| 2019 | -27.2 million USD | 42.1 million USD |
| 2018 | -64.3 million USD | 10.6 million USD |
| 2017 | -38.7 million USD | 17.5 million USD |
| 2016 | -13.7 million USD | 25.2 million USD |
| 2015 | -16.4 million USD | 10.4 million USD |
MRSN
Price: $3.52
52 week price:
Earnings Per Share: -1.48 USD
P/E Ratio: -2.20
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 915100
Ebitda: -7.8 millionMarket Capitalization: 462.2 million